Sea Purity Investment Portfolio
Software Vertical
Disruptive Technology Products
Socially Responsible Investing
Pharma / Biotech
Medtech / Device
Consumer
Alternative Funds
Real Estate
Significant Wins and Exits
By investing in a great consumer fintek platform, we realized a nearly 12x Return from our seed investment
Dosh completed its sale to Cardlytics on March 9th 2021. This was a 13x return for Sea Purity.
Company announces that its PRV-031 therapeutic helps delay the onset of Type 1 Diabetes by up to 2 years for High Risk individuals. We generated a 7x return from our Pre-IPO round investment.
KKR purchases minority stake in Arbor Pharmaceuticals at a valuation of over $1 Billion.
Novartis purchases Encore for $500 million creating a 12x return with the potential for up to 12x in milestone earn outs.
Purchased by Great Hill Partners for $40.50 per share.
Former management team of AbbVie subsidiary purchases 17% interest and stock trades into the $20’s.
Pre-IPO investment which netted a 500% return.
Location
San Clemente, CA, United States
Phone
949-391-0980
matt.hayden@seapurity.us
